Meeting
2017 ASCO Annual Meeting
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
Authors
Gerard Zalcman
GH Bichat Claude Bernard, Paris, France
Gerard Zalcman , Solange Peters , Aaron Scott Mansfield , Thierry Marie Jahan , Sanjay Popat , Arnaud Scherpereel , Wenhua Hu , Giovanni Selvaggi , Paul Baas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT02899299
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS8581)
DOI
10.1200/JCO.2017.35.15_suppl.TPS8581
Abstract #
TPS8581
Poster Bd #
314a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt D. Galsky
First Author: Matt D. Galsky
Poster
2018 ASCO Annual Meeting
A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
First Author: Matt D. Galsky